Therapeutic Delivery – Products

To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scientific Inc. is expanding its oral solid dose (OSD) footprint with a $22-million total investment.

Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology.

Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.

BioSpring GmbH and Pantherna Therapeutics GmbH, have agreed on a strategic collaboration in the field of research and development and signed a cooperation agreement mid-July.

Biora Therapeutics, Inc. has shared positive topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment of ulcerative colitis.

The collaborative center will help to lower barriers to RNA innovation and discovery.

N4 Pharma Plc, the company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI.

Applied Biophysics Forum promises real-world data from nucleic acid drug delivery researchers.

Optimer delivery vehicle has been shipped to a pharma partner for external evaluation. The specific delivery vehicle could generate new precision therapies for liver disease.

In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, German pharmatech company, leon-nanodrugs GmbH (LEON), proudly announces a pioneering technical evaluation by CMAC, University of Strathclyde.